Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? - Annals of Oncology
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer | HTML
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer - ppt download
Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
Dose-Dense Chemotherapy – Callaix
Dr Sunil Verma on Twitter: "Dr. Gray sharing data on chemotherapy schedule impact on breast cancer outcome - overall improved outcome with dose dense approach #SABCS17 https://t.co/1TvnDXVFpu" / Twitter
Myeloid Growth Factor Support for Dose-Dense Adjuvant Chemotherapy for Breast Cancer
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival – A retrospective multi-centre cohort study of ...
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
![PDF] The dose-dense principle in chemotherapy. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6c36a4f67d16b6fd3b91bd33f3bf6afc52785061/4-Figure3-1.png "PDF] The dose-dense principle in chemotherapy. | Semantic Scholar")
PDF] The dose-dense principle in chemotherapy. | Semantic Scholar
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
